Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 8/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1303041 | 1.00 | LMNA (0.42) | LMNACYP2C19HSD17B10ACEREN | |
| SCHEMBL4270704 | 1.00 | LMNA (0.42) | LMNACYP2C19HSD17B10ACEREN | |
| SCHEMBL1661629 | 0.94 | LMNA (0.38) | LMNACYP2C19HSD17B10ACEREN | |
| SCHEMBL3666957 | 0.86 | — | — | |
| SCHEMBL1302797 | 0.81 | AR (0.36) | LMNACYP2C19HSD17B10 | |
| SCHEMBL3967423 | 0.81 | ACE (0.40) | ACEREN | |
| SCHEMBL707281 | 0.81 | CTSL (0.47) | — | |
| SCHEMBL6039382 | 0.81 | LMNA (0.34) | LMNACYP2C19HSD17B10ACEREN | |
| SCHEMBL707280 | 0.81 | CTSL (0.47) | — | |
| SCHEMBL556078 | 0.81 | AR (0.36) | LMNACYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-07-25 | — | — | US | claimed |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-03-09 | — | — | US | claimed |
| EP-3860984-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-08-11 | — | — | EP | claimed |
| CN-112912371-A | Flavone derivatives for treating and preventing hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2021-06-04 | — | — | CN | claimed |
| WO-2020070088-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-04-09 | — | — | WO | claimed |
| US-9249163-B2 | PDE10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV. (BE) | 2016-02-02 | — | — | US | claimed |
| US-9193736-B2 | PDE 10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2015-11-24 | — | — | US | claimed |
| WO-2014200885-A1 | PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-18 | — | — | WO | claimed |
| WO-2014200882-A1 | PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-18 | — | — | WO | claimed |
| US-20140364413-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | claimed |
| WO-1996021647-A1 | SUBSTITUTED 2-PHENYLPYRIDINES AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1996-07-18 | — | — | WO | claimed |
| EP-0669334-A1 | TRICYCLIC COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-08-30 | — | — | EP | claimed |
| US-5250677-A | Anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-10-05 | — | — | US | claimed |
| US-5175283-A | Enzyme inhibitors for antitrypsin or antithrombin as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 1992-12-29 | — | — | US | claimed |
| US-5110812-A | Treatment of pancreatitis; anticoagulants | BRISTOL-MYERS SQUIBB CO. (US) | 1992-05-05 | — | — | US | claimed |
| EP-0245357-B1 | ANGIOSTATIC STEROIDS | THE UPJOHN COMPANY (US) | 1991-08-07 | — | — | EP | claimed |
| US-5037819-A | Anticoagulant; treating pancreatitis | BRISTOL-MYERS SQUIBB COMPANY (US) | 1991-08-06 | — | — | US | claimed |
| EP-0156643-B1 | ESTER PRODRUGS OF STEROIDS | THE UPJOHN COMPANY (US) | 1990-08-08 | — | — | EP | claimed |
| WO-1982000402-A1 | HERBICIDAL AND PLANT GROWTH REGULANT DIPHENYLPYRIDAZINONES | DIAMOND SHAMROCK CORP (US) | 1982-02-18 | — | — | WO | claimed |
| EP-0046069-A1 | Herbicidal and plant growth regulant diphenylpyridazinones | DIAMOND SHAMROCK CORPORATION (US) | 1982-02-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364413-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | PDE2A, PDE3B, PDE3A | LMNA 1417/4885CYP2C19 761/4885HSD17B10 127/4885 |
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | CCNE2, CCNE1, CCNT1 | LMNA 1778/4885CYP2C19 152/4885HSD17B10 902/4885 |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | CCNE2, CCNE1, CCNT1 | LMNA 1778/4885CYP2C19 152/4885HSD17B10 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.